Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 trial Evaluating TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

Phase 1b/2 trial Evaluating TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Maplirpacept (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Nov 2022 According to a Pfizer media release, the study is sponsored and funded by Pfizer and Sanofi will provide SARCLISA for the study.
    • 01 Nov 2022 According to a Pfizer media release, Pfizer and Sanofi U.S. Services Inc. (Sanofi) entered into a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combination of TTI-622, and SARCLISA (isatuximab-irfc) plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy. This trial will be conducted under the terms of this agreement.
    • 30 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top